{
  "id": 13064106,
  "title": "TRexBio prices $117M IPO for Tregs as Retension lands $45M Nasdaq debut for hypertension",
  "url": "https://urgent.news/2026/10/09/trexbio-prices-117m-ipo-for-tregs-as-retension-lands-45m-nasdaq-debut",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-09T07:54:45.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/trexbio-prices-117m-ipo-for-tregs-as-retension-lands-45m-nasdaq-debut-for-hypertension/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The appetite for biotech IPOs remains strong, especially when Eli Lilly and Nobel Prize-winning science are involved. TRexBio priced its initial stock sale Thursday, raising $116.7 million in ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "TRexBio prices IPO at $14 per share, expects $116.7M",
        "url": "https://urgent.news/2026/10/09/trexbio-prices-ipo-at-14-per-share-expects-116-7m",
        "published": "2026-10-09T01:36:29.000Z"
      },
      {
        "outlet": "Nasdaq Markets",
        "title": "Retension Pharmaceuticals Prices $45 Million IPO At $12 Per Share",
        "url": "https://urgent.news/2026/10/09/retension-pharmaceuticals-prices-45-million-ipo-at-12-per-share",
        "published": "2026-10-09T04:40:37.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}